Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast. 1998

J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
Molecular Pathology Division, Department of Cellular Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA. lichy@email.afip.osd.mil

Microdissection of histologically identifiable components from formalin-fixed, paraffin-embedded tissue sections allows molecular genetic analyses to be correlated directly with pathological findings. In this study, we have characterized loss of heterozygosity (LOH) at chromosome 11p15 at different stages of progression in microdissected tumor components from 115 ductal carcinomas of the breast. Microdissected foci of intraductal, infiltrating, and metastatic tumors were analyzed to determine the stage of progression at which LOH at 11p15 occurs. LOH was detected in 43 (37%) of 115 cases. Foci of intraductal carcinoma could be microdissected from 85 cases, of which 30 (35%) showed LOH at some stage of progression. LOH was detected in the intraductal component in 26 of these 30 cases. Interstitial deletions were characterized by using a panel of 10 highly polymorphic markers. The smallest region of overlap (SRO) for LOH at 11p15 was bounded by the markers D11S4046 and D11S1758. LOH at 11p15.5 showed no correlation with estrogen receptor status, the presence of positive lymph nodes, tumor size, histological grade, or long-term survival. We conclude that 11p15 LOH usually occurs early in breast cancer development but less frequently does not develop until the infiltrating or metastatic stages of tumor progression.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002880 Chromosomes, Human, Pair 11 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 11
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D018270 Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST. Carcinoma, Infiltrating Duct,Carcinoma, Invasive Ductal, Breast,Carcinoma, Mammary Ductal,Invasive Ductal Carcinoma, Breast,Mammary Ductal Carcinoma,Carcinomas, Infiltrating Duct,Carcinomas, Mammary Ductal,Mammary Ductal Carcinomas
D019656 Loss of Heterozygosity The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted. Allelic Loss,Heterozygosity, Loss of,Allelic Losses,Heterozygosity Loss

Related Publications

J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
September 1995, Journal of the National Cancer Institute,
J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
March 1999, Human pathology,
J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
May 1998, British journal of cancer,
J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
February 1995, The Journal of pathology,
J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
January 1997, The American journal of pathology,
J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
October 2001, Zhonghua er bi yan hou ke za zhi,
J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
January 1996, Acta cytologica,
J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
November 1996, Cancer research,
J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
October 2012, Human pathology,
J H Lichy, and M Zavar, and M M Tsai, and T J O'Leary, and J K Taubenberger
April 1987, Proceedings of the National Academy of Sciences of the United States of America,
Copied contents to your clipboard!